Literature DB >> 8971034

The 5' ends of Thogoto virus (Orthomyxoviridae) mRNAs are homogeneous in both length and sequence.

C Albo1, J Martín, A Portela.   

Abstract

Thogoto (THO) virus is a tick-borne member of the Orthomyxoviridae whose genome consists of six segments of linear, negative sense, single-stranded RNA. To gain insight into the mechanism by which viral mRNA transcripts are initiated, poly(A)+ RNA isolated from THO virus-infected cells was characterized by (i) primer extension experiments, (ii) immunoprecipitation studies with an anticap monoclonal antibody, (iii) direct sequencing analysis of the isolated RNA, and (iv) cloning and sequencing of individual mRNA molecules. The results indicated that THO virus mRNAs are capped and homogeneous in both length and sequence at their 5' end. These findings contrast with the situation found in all other segmented, negative sense or ambisense, single-stranded RNA viruses so far analyzed in which the 5' ends of viral mRNAs are heterogeneous in length and sequence. These results are discussed in terms of the mechanism used by THO virus to initiate mRNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971034      PMCID: PMC191002     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Oriented synthesis and cloning of influenza virus nucleoprotein cDNA that leads to its expression in mammalian cells.

Authors:  A Portela; J A Melero; C Martínez; E Domingo; J Ortín
Journal:  Virus Res       Date:  1985-12       Impact factor: 3.303

2.  Transfer of 5'-terminal cap of globin mRNA to influenza viral complementary RNA during transcription in vitro.

Authors:  S J Plotch; M Bouloy; R M Krug
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

3.  Structure of the host-derived sequences present at the 5' ends of influenza virus mRNA.

Authors:  A J Caton; J S Robertson
Journal:  Nucleic Acids Res       Date:  1980-06-25       Impact factor: 16.971

4.  Polyadenylation sites for influenza virus mRNA.

Authors:  J S Robertson; M Schubert; R A Lazzarini
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

5.  Nonviral oligonucleotides at the 5' terminus of cytoplasmic influenza viral mRNA deduced from cloned complete genomic sequences.

Authors:  R Dhar; R M Chanock; C J Lai
Journal:  Cell       Date:  1980-09       Impact factor: 41.582

6.  The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity.

Authors:  U Desselberger; V R Racaniello; J J Zazra; P Palese
Journal:  Gene       Date:  1980-02       Impact factor: 3.688

7.  Nuclear accumulation of influenza viral RNA transcripts and the effects of cycloheximide, actinomycin D, and alpha-amanitin.

Authors:  G E Mark; J M Taylor; B Broni; R M Krug
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

8.  A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription.

Authors:  S J Plotch; M Bouloy; I Ulmanen; R M Krug
Journal:  Cell       Date:  1981-03       Impact factor: 41.582

9.  The 5' ends of Hantaan virus (Bunyaviridae) RNAs suggest a prime-and-realign mechanism for the initiation of RNA synthesis.

Authors:  D Garcin; M Lezzi; M Dobbs; R M Elliott; C Schmaljohn; C Y Kang; D Kolakofsky
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Cap and internal nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary RNA during transcription in vitro.

Authors:  M Bouloy; M A Morgan; A J Shatkin; R M Krug
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

View more
  12 in total

1.  Hairpin loop structure in the 3' arm of the influenza A virus virion RNA promoter is required for endonuclease activity.

Authors:  M B Leahy; H C Dobbyn; G G Brownlee
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Striking conformational similarities between the transcription promoters of Thogoto and influenza A viruses: evidence for intrastrand base pairing in the 5' promoter arm.

Authors:  M B Leahy; J T Dessens; P A Nuttall
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  In vitro polymerase activity of Thogoto virus: evidence for a unique cap-snatching mechanism in a tick-borne orthomyxovirus.

Authors:  M B Leahy; J T Dessens; P A Nuttall
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  An endonuclease switching mechanism in the virion RNA and cRNA promoters of Thogoto orthomyxovirus.

Authors:  M B Leahy; J T Dessens; D C Pritlove; P A Nuttall
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Thogoto virus matrix protein is encoded by a spliced mRNA.

Authors:  G Kochs; F Weber; S Gruber; A Delvendahl; C Leitz; O Haller
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Rescue of recombinant Thogoto virus from cloned cDNA.

Authors:  E Wagner; O G Engelhardt; S Gruber; O Haller; G Kochs
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Mx1 in Hematopoietic Cells Protects against Thogoto Virus Infection.

Authors:  Jan Spitaels; Lien Van Hoecke; Kenny Roose; Georg Kochs; Xavier Saelens
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

8.  The putative polymerase sequence of infectious salmon anemia virus suggests a new genus within the Orthomyxoviridae.

Authors:  B Krossøy; I Hordvik; F Nilsen; A Nylund; C Endresen
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  The interferon antagonist ML protein of thogoto virus targets general transcription factor IIB.

Authors:  Carola Vogt; Ellen Preuss; Daniel Mayer; Friedemann Weber; Martin Schwemmle; Georg Kochs
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

10.  Non coding extremities of the seven influenza virus type C vRNA segments: effect on transcription and replication by the type C and type A polymerase complexes.

Authors:  Bernadette Crescenzo-Chaigne; Cyril Barbezange; Sylvie van der Werf
Journal:  Virol J       Date:  2008-10-30       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.